What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Surgery, Ipilimumab, Melanoma and Oncology.
In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.
His work focuses on many connections between Surgery and other disciplines, such as Hazard ratio, that overlap with his field of interest in Intention-to-treat analysis and Adjuvant therapy.
His studies in Ipilimumab integrate themes in fields like Phases of clinical research, Randomized controlled trial, Talimogene laherparepvec, Prospective cohort study and Survival analysis.
He has researched Melanoma in several fields, including Survival rate and Nivolumab.
He interconnects Avelumab, Pathology, Antibody and Monoclonal in the investigation of issues within Oncology.
His most cited work include:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (5176 citations)
- Pembrolizumab for the treatment of non-small cell lung cancer (3324 citations)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma (3250 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Melanoma, In patient and Ipilimumab.
His research in Internal medicine intersects with topics in Gastroenterology and Surgery.
His Surgery research is multidisciplinary, relying on both Urology and Hazard ratio.
His Oncology study combines topics from a wide range of disciplines, such as Advanced melanoma, Immunotherapy, Chemotherapy, Dabrafenib and Cohort.
His Melanoma research focuses on subjects like Cancer, which are linked to Lung cancer.
His work in Ipilimumab covers topics such as Talimogene laherparepvec which are related to areas like Oncolytic virus.
He most often published in these fields:
- Internal medicine (66.18%)
- Oncology (47.06%)
- Melanoma (42.65%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.18%)
- Oncology (47.06%)
- Melanoma (42.65%)
In recent papers he was focusing on the following fields of study:
Omid Hamid mostly deals with Internal medicine, Oncology, Melanoma, In patient and Ipilimumab.
His study in Randomized controlled trial, Pembrolizumab, Adverse effect, Hazard ratio and Clinical trial is carried out as part of his Internal medicine studies.
The study incorporates disciplines such as Meta-analysis, Cancer and PD-L1 in addition to Hazard ratio.
His studies deal with areas such as Tolerability, Clinical endpoint, Metastasis, Cohort and Immunotherapy as well as Oncology.
His work carried out in the field of Melanoma brings together such families of science as Targeted therapy, MEK inhibitor, Trametinib and Rash.
His research investigates the connection between Ipilimumab and topics such as Gastroenterology that intersect with issues in Toxicity.
Between 2018 and 2021, his most popular works were:
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (244 citations)
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (214 citations)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. (110 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Omid Hamid mainly focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Adverse effect.
Internal medicine is often connected to Gastroenterology in his work.
His Melanoma study combines topics in areas such as Atezolizumab and Antigen.
His Oncology study incorporates themes from Metastasis and Immunotherapy.
His research is interdisciplinary, bridging the disciplines of Nivolumab and Ipilimumab.
His Adverse effect study which covers Rash that intersects with Metastatic melanoma, Epacadostat, Cohort and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
